Oligonucleotide (siRNA) · Gene silencing: MMP7 · developed by ARROWHEAD PHARMACEUTICALS
ARO-MMP7 is a small interfering RNA (siRNA) that reduces MMP7 (matrix metalloproteinase 7) expression. It is administered by inhalation as a nebulized solution and is being studied in idiopathic pulmonary fibrosis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05537025 | Phase 1/2 | Idiopathic Pulmonary Fibrosis | Completed | ARWR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Idiopathic Pulmonary Fibrosis
Updated Oct 3, 2026. Something wrong or missing? Report it on the ARWR page.
See ARWR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ARWR catalysts and pipeline →